Program Goals

This activity is designed to meet the educational needs of healthcare and laboratory professionals involved in the research, diagnosis and treatment of hematological malignancies, such as Myelodysplastic Syndrome (MDS) and Myeloproliferative Disorders (MPD).

Target Audience

Hematology oncologists, hematopathologists, clinical laboratory and other healthcare professionals interested in the management of patients with hematological malignancies.

Educational Objectives

After completing this activity, the participant should be able to:
  1. Summarize the clinical data regarding the importance of detecting chromosomal anomalies in MDS and MPD
  2. Discuss how the detection of these anomalies drives important decisions for therapy in these diseases
  3. Explain the diagnostic tests available for detecting these anomalies
  4. Discuss the importance of detecting these [potentially cryptic] anomalies with Fluorescence in situ Hybridization (FISH)

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Collaborative (MEC) and Dane Garvin Ltd. Medical Education Collaborative is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation – Physician, CME

Medical Education Collaborative designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Designation – Lab Professional, P.A.C.E.®

The American Society for Clinical Laboratory Science’s Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program will provide 1.5 contact hour of credit

Commercial Support Statement

This activity is supported by an educational grant from Abbott Molecular.

Faculty

Stephen D. Nimer, MD
Head, Division of Hematologic Oncology
Chief, Hematology Service
Memorial-Sloan Kettering Cancer Center

Suresh C. Jhanwar, PhD
Director, Cytogenetics Laboratory
Memorial-Sloan Kettering Cancer Center

Disclosure of Conflicts of Interests

Instructors, planners, managers and other individuals who are in a position to control the content of this activity are required to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty Disclosures

Name Type Commercial Supporter
Stephen D. Nimer, MD
 N.A.
 N.A.
Suresh C. Jhanwar, PhD
 N.A.
 N.A.
Employees of Medical Education Collaborative, the accredited provider for this activity, have disclosed that they have no significant financial relationships.

How to Obtain CME Credit

Viewers are expected to visit all presentations before attempting to take the test and activity evaluation. Successful completion will lead to the issuance of a certificate for 1.5 AMA PRA Category 1 Credit(s) ™. To receive credit, the course must be completed before June 2008.

If you attended the live presentation on May 1st, 2007, and have received CME credit for this program, you are not eligible for additional credit.

Participation in this activity should be completed in approximately 1.5 hours. Please follow these steps in order to receive CME credit for viewing the webcast:
  • Read all of the CME accreditation information above.
  • View the complete webcast program.
  • Click on the link to apply for CME credits.
  • Complete the online registration (registration is free).
  • Complete the online test and/or evaluation. Participants must receive a test score of at least 70% and answer all evaluation questions to receive a certificate.
  • After successfully completing the online test and evaluation, your application will be processed by the CME provider and your certificate will be sent to you. Please allow 3-4 weeks for this process.

Should you have any CME questions regarding this activity, please contact:
Medical Education Collaborative
651 Corporate Circle, Suite 104
Golden, CO 80401
866.420.3252 (toll free)
303.420.3259 (fax)
http://www.meccme.org/

How to Obtain P.A.C.E.® Credit

Viewers are expected to complete the presentation before attempting to submit contact information and the session evaluation. Successful completion will lead to the issuance of a certificate for 1.5 contact hour of P.A.C.E.® approved continuing education. To receive credit, the course must be completed before June 2009. No post-test is required through October 30, 2007; after that date a quiz must be completed to earn credit.

If you attended the live presentation on May 1st, 2007, and have already received P.A.C.E.® credit for this program, you are not eligible for additional credit.

Participation in this activity should be completed in approximately 1.5 hours. Please follow these steps in order to receive P.A.C.E.® credit for viewing the webcast:

  • Read all of the information above.
  • View the complete webcast program.
  • Click on the link to apply for P.A.C.E.® credit.
  • Complete the online registration (registration is free).
  • Complete the online test and/or evaluation. Participants must receive a test score of at least 70% (if taken after October 30, 2007) and answer all evaluation questions to receive a certificate.
  • After successfully completing the online test and/or evaluation, your application will be processed by the CE provider and your certificate will be sent to you via email. Please allow 3-4 weeks for this process.

Should you have any P.A.C.E.® questions regarding this activity, please contact:
ASCLS P.A.C.E.®
6701 Democracy Blvd., Suite 300
Bethesda, MD 20817-1574
Ph: 301-657-2768
Fx: 301-657-2909
http://www.ascls.org/

For technical difficulties, please consult our Technical Instructions.

Release date: May 2007
Expiration date: June 2009


"Guiding Therapy Decisions for Hematological Malignancies with Molecular Genetic Testing"